Children with multiple sclerosis should not become therapeutic hostages
Therapeutic Advances In Neurological DisordersPeer ReviewedKlaus Rose +12016Journals
Both the United States (US) Food and Drug Administration (FDA) and the European Union (EU) European Medicines Agency (EMA) order pediatric clinical trials as a condition for approval of new compounds. We evaluate clinical value and likelihood of sufficient recruitment for pediatric multiple sclerosis (pMS) studies and discuss US and EU pediatric legislation with pMS as a paradigm.
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support